Gene therapy biotech Solid Biosciences sets terms for $100 million IPO – Nasdaq
|
Gene therapy biotech Solid Biosciences sets terms for $100 million IPO
Nasdaq Solid Biosciences, which is developing a gene therapy to treat Duchenne muscular dystrophy (DMD), announced terms for its IPO on Tuesday. The Cambridge, MA-based company plans to raise $100 million by offering 5.9 million shares at a price range of $16 … |
